Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Understanding how inherited and acquired mutations interact to affect cancer

Germline and somatic variants in the p53 pathway cooperate to influence cancer risk, progression and response to therapy.

Celebrating 100 years of women in Oxford Medical Sciences

Ludwig Oxford Director Professor Xin Lu features in this showcase of women in diverse roles across Oxford’s Medical Sciences Division.

Vacancy: Postdoctoral Researcher in Mutagenesis


Grade 7: Salary in range £32,817 - £40,322 per annum

How to make blood vessels different

Professor Sarah De Val, Dr Alice Neal and Dr Svanhild Nornes investigate the role of ETS factors in blood vessel specification.

Vacancy: Postdoctoral Research Scientist in RNA Modification and Epigenetics


Grade 7: Salary in range £32,817 - £40,322 per annum

The role of Met1-linked ubiquitin signalling in inflammation and infection

Professor Mads Gyrd-Hansen reviews the current knowledge about this important post-translational modification.

Novel mechanism of repressive chromatin regulation in mammals

Professor Yang Shi uncovers a new role for RNA methylation and the RNA methyltransferase METTL3 in the maintenance of heterochromatin

New sequencing methods for distinguishing DNA modifications

Dr Chunxiao Song’s team have expanded their suite of bisulphite-free DNA modification sequencing methods to specifically and directly detect each of the four modifications made to the DNA base cytosine

Cancer epigeneticist Stephen B. Baylin joins Ludwig Oxford as a Visiting Professor

Ludwig Oxford welcomes this leading international figure in the field of cancer epigenetics

Drugging p53

The drug arsenic trioxide can restore the structure and function of some p53 tumour suppressor mutants, with potential as a future personalised cancer treatment strategy.

Q&A with Yang Shi

Ludwig Oxford’s newest recruit is interviewed in the latest edition of the Ludwig Link.

Bioengineering the human gut

An interdisciplinary collaboration generates an advanced model of the human gastrointestinal tract with broad applications for disease research and regenerative medicine.

Using AI to improve the quality of endoscopy videos

A multidisciplinary team of researchers has developed a deep-learning framework for improving endoscopy to aid cancer detection.

In conversation with Xin Lu

Ludwig Oxford Director Professor Xin Lu features in this edition of the FEBS Journal.

Ludwig Oxford alumni’s biotech success

Scenic Biotech, co-founded by former Ludwig Oxford group leader Sebastian Nijman, collaborates with Roche group member Genentech in a $375m deal.

$410 million buy out for Ludwig Oxford cancer detection technology

Oxford spin-out Base Genomics is acquired by early cancer detection company Exact Sciences.

CRUK Oxford Centre Symposium 2020

Two Ludwig Oxford group leaders present their work at this year’s virtual gathering of the Oxford cancer community.

Probing proteasomal subtypes

Professor Benoit Van den Eynde’s lab compares the abilities of four proteasome subtypes to degrade ubiquitinated or oxidised proteins.

Chunxiao Song: The chemical biologist

Ludwig Oxford’s Dr Chunxiao Song is featured in Ludwig Cancer Research’s Annual Research Highlights Report.

Investigating mechanisms of gene repression

Skirmantas Kriaucionis’ lab teases apart the contributions of different mechanisms to repress gene expression.

Load More